title: ÐÐ¾Ð¸ÑÐº Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½ÑÑ Ð¼Ð¸ÑÐµÐ½ÐµÐ¹ Ð´Ð»Ñ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ ÑÐ°ÐºÐ° Ð»ÑÐ³ÐºÐ¾Ð³Ð¾
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¼Ð°Ð³Ð¸ÑÑÑÐ°
titleType: Subtitle
title: Search of potential targets for target therapy of lung cancer
Creators: name: ÐÑÐ»ÐºÐ¸Ð´Ð¶Ð°Ð½, Ð Ð¸Ð¼Ð¼Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2023
Subjects: ÑÐ°Ðº Ð»ÐµÐ³ÐºÐ¾Ð³Ð¾
Ð½Ð¾Ð²ÑÐµ Ð¼Ð¸ÑÐµÐ½Ð¸ Ð´Ð»Ñ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸
ÑÑÐ°Ð½ÑÐ»Ð¾ÐºÐ°ÑÐ¸Ð¸
ÐºÐ¸Ð½Ð°Ð·Ñ
Ð¿ÑÑ
ngs
lung cancer
new targets for targeted therapy
translocations
kinases
pcr

description: ÐÐ°Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° Ð°ÐºÑÑÐ°Ð»ÑÐ½Ð¾Ð¼Ñ Ð²Ð¾Ð¿ÑÐ¾ÑÑ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¸Ñ Ð½Ð¾Ð²ÑÑ Ð¼Ð¸ÑÐµÐ½ÐµÐ¹ Ð´Ð»Ñ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ ÑÐ°ÐºÐ° Ð»ÐµÐ³ÐºÐ¾Ð³Ð¾. Ð¦ÐµÐ»ÑÑ Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ ÑÐ²Ð»ÑÐµÑÑÑ Ð¿Ð¾Ð¸ÑÐº Ð½Ð¾Ð²ÑÑ ÑÐ¾Ð¼Ð°ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð°ÐºÑÐ¸Ð²Ð¸ÑÑÑÑÐ¸Ñ ÑÑÐ°Ð½ÑÐ»Ð¾ÐºÐ°ÑÐ¸Ð¹ Ñ ÑÑÐ°ÑÑÐ¸ÐµÐ¼ Ð³ÐµÐ½Ð¾Ð², ÐºÐ¾Ð´Ð¸ÑÑÑÑÐ¸Ñ Ð±ÐµÐ»ÐºÐ¸ Ñ ÐºÐ¸Ð½Ð°Ð·Ð½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð½Ð¾ÑÑÑÑ, ÐºÐ¾ÑÐ¾ÑÑÐµ Ð¼Ð¾Ð³ÑÑ Ð±ÑÑÑ Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½ÑÐ¼Ð¸ Ð¼Ð¸ÑÐµÐ½ÑÐ¼Ð¸ Ð´Ð»Ñ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÐ°Ð¼Ð¸ ÐºÐ¸Ð½Ð°Ð· Ð² Ð»ÐµÑÐµÐ½Ð¸Ð¸ ÑÐ°ÐºÐ° Ð»ÐµÐ³ÐºÐ¾Ð³Ð¾, Ð·Ð°Ð½Ð¸Ð¼Ð°ÑÑÐµÐ³Ð¾ Ð²ÐµÐ´ÑÑÐ¸Ðµ Ð¿Ð¾Ð·Ð¸ÑÐ¸Ð¸ Ð² ÑÑÑÑÐºÑÑÑÐµ ÑÐ¼ÐµÑÑÐ½Ð¾ÑÑÐ¸ Ð¾Ñ Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸ÑÐµÑÐºÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹. Ð­ÐºÑÑÑÐ°ÐºÑÐ¸Ñ Ð ÐÐ Ð¸Ð· Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸Ð»Ð°ÑÑ ÐºÐ¾Ð¼Ð¼ÐµÑÑÐµÑÐºÐ¸Ð¼Ð¸ Ð½Ð°Ð±Ð¾ÑÐ°Ð¼Ð¸ Ð² ÑÐ»ÑÑÐ°Ðµ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð³Ð¾ ÑÐµÐºÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² (NGS) Ð¸ ÑÐµÐ½Ð¾Ð»-ÑÐ»Ð¾ÑÐ¾ÑÐ¾ÑÐ¼Ð½ÑÐ¼ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ Ð² ÑÐ»ÑÑÐ°Ðµ ÑÐºÑÐ¸Ð½Ð¸Ð½Ð³Ð° Ð½Ð°Ð¹Ð´ÐµÐ½Ð½ÑÑ ÑÑÐ°Ð½ÑÐ»Ð¾ÐºÐ°ÑÐ¸Ð¹ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ Ð¿Ð¾Ð»Ð¸Ð¼ÐµÑÐ°Ð·Ð½Ð¾Ð¹ ÑÐµÐ¿Ð½Ð¾Ð¹ ÑÐµÐ°ÐºÑÐ¸Ð¸ Ð½Ð° ÑÐ°ÑÑÐ¸ÑÐµÐ½Ð½Ð¾Ð¹ Ð²ÑÐ±Ð¾ÑÐºÐµ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² ÑÐ°ÐºÐ° Ð»ÐµÐ³ÐºÐ¾Ð³Ð¾. ÐÐ°ÑÐµÑÑÐ²Ð¾ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² Ð¾ÑÐµÐ½Ð¸Ð²Ð°Ð»Ð¾ÑÑ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ ÑÑÐ°Ð³Ð¼ÐµÐ½ÑÐ½Ð¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð¸ ÑÐ»ÑÐ¾Ð¼ÐµÑÑÐ¸ÑÐµÑÐºÐ¸Ð¼ Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼. Ð¢Ð°ÐºÐ¶Ðµ Ð´Ð»Ñ Ð°Ð½Ð°Ð»Ð¸ÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ»Ð¸ Ð·Ð°Ð´ÐµÐ¹ÑÑÐ²Ð¾Ð²Ð°Ð½Ñ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÐµ Ð¸Ð½ÑÐµÑÐ½ÐµÑ-ÑÐµÑÑÑÑÑ, Ð°ÑÐ»Ð°ÑÑ Ð¸ Ð±Ð°Ð·Ñ Ð´Ð°Ð½Ð½ÑÑ. Ð ÑÐ¾Ð´Ðµ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ»Ð° ÑÑÐ¾ÑÐ¼Ð¸ÑÐ¾Ð²Ð°Ð½Ð° ÐºÐ¾Ð»Ð»ÐµÐºÑÐ¸Ñ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ¹ Ð»ÐµÐ³ÐºÐ¾Ð³Ð¾ Ð´Ð»Ñ Ð¿Ð¾Ð¸ÑÐºÐ° Ð½Ð¾Ð²ÑÑ Ð¼Ð¸ÑÐµÐ½ÐµÐ¹ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸. ÐÑÐ±Ð¾ÑÐºÐ° Ð¸Ð· 101 Ð¾Ð±ÑÐ°Ð·ÑÐ° Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ¹ Ð»ÐµÐ³ÐºÐ¾Ð³Ð¾ Ð±ÐµÐ· ÑÐ°ÑÐ°ÐºÑÐµÑÐ½ÑÑ Ð´Ð»Ñ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð½Ð¾Ð²Ð¾Ð¾Ð±ÑÐ°Ð·Ð¾Ð²Ð°Ð½Ð¸Ñ Ð°ÐºÑÐ¸Ð²Ð¸ÑÑÑÑÐ¸Ñ ÑÐ¾Ð±ÑÑÐ¸Ð¹ Ð±ÑÐ»Ð° Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð° Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ NGS. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ Ð±ÑÐ»Ð¸ Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ñ 27 ÑÐ¸Ð¼ÐµÑÐ½ÑÑ ÑÑÐ°Ð½ÑÐºÑÐ¸Ð¿ÑÐ¾Ð² Ð±ÐµÐ· ÑÐ´Ð²Ð¸Ð³Ð° ÑÐ°Ð¼ÐºÐ¸ ÑÑÐ¸ÑÑÐ²Ð°Ð½Ð¸Ñ, 21 Ð¸Ð· ÐºÐ¾ÑÐ¾ÑÑÑ Ð±ÑÐ»Ð¸ Ñ ÑÐ°ÑÑÐ¸ÑÐ½Ð¾/Ð¿Ð¾Ð»Ð½Ð¾ÑÑÑÑ ÑÐ¾ÑÑÐ°Ð½Ð½ÑÐ¼ ÐºÐ¸Ð½Ð°Ð·Ð½ÑÐ¼ Ð´Ð¾Ð¼ÐµÐ½Ð¾Ð¼. ÐÐµÑÐ¾Ð´Ð¾Ð¼ ÐÐ¦Ð  ÑÐ´Ð°Ð»Ð¾ÑÑ Ð²ÐµÑÐ¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°ÑÑ 17 Ð¿ÐµÑÐµÑÑÑÐ¾ÐµÐº, Ð½Ð° Ð¿ÑÐ¸ÑÑÑÑÑÐ²Ð¸Ðµ ÐºÐ¾ÑÐ¾ÑÑÑ Ð±ÑÐ»Ð¸ Ð¿ÑÐ¾ÑÐµÑÑÐ¸ÑÐ¾Ð²Ð°Ð½Ñ 1069 ÑÐµÑÑÐ¾ÑÐ¿ÐµÐºÑÐ¸Ð²Ð½ÑÑ Ð¿Ð¾ÑÐ»ÐµÐ´Ð¾Ð²Ð°ÑÐµÐ»ÑÐ½ÑÑ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² ÑÐ°ÐºÐ° Ð»ÐµÐ³ÐºÐ¾Ð³Ð¾, Ð³Ð´Ðµ Ð½Ðµ Ð±ÑÐ»Ð¸ Ð½Ð°Ð¹Ð´ÐµÐ½Ñ ÑÐ°ÑÐ°ÐºÑÐµÑÐ½ÑÐµ Ð´Ð»Ñ Ð´Ð°Ð½Ð½Ð¾Ð¹ Ð½ÐµÐ¾Ð¿Ð»Ð°Ð·Ð¸Ð¸ Ð´ÑÐ°Ð¹Ð²ÐµÑÐ½ÑÐµ Ð¼ÑÑÐ°ÑÐ¸Ð¸. Ð ÑÐµÐ·ÑÐ»ÑÑÐ°ÑÐµ ÑÐ°Ð±Ð¾ÑÑ ÑÐ´Ð°Ð»Ð¾ÑÑ Ð¾Ð±Ð½Ð°ÑÑÐ¶Ð¸ÑÑ 2 Ð¿Ð¾Ð²ÑÐ¾ÑÑÑÑÐ¸ÐµÑÑ ÑÑÐ°Ð½ÑÐ»Ð¾ÐºÐ°ÑÐ¸Ð¸: ADK::KAT6B Ð¸ RPS6KB1::VMP1. ÐÑÑÐ²Ð»ÐµÐ½Ð¸Ðµ Ð½Ð¾Ð²ÑÑ Ð¿Ð¾Ð²ÑÐ¾ÑÑÑÑÐ¸ÑÑÑ Ð¿ÐµÑÐµÑÑÑÐ¾ÐµÐº Ð¸ Ð·Ð½Ð°ÑÐ¸Ð¼ÑÑ ÑÐ½Ð¸ÐºÐ°Ð»ÑÐ½ÑÑ ÑÐ¸Ð¼ÐµÑÐ½ÑÑ ÑÑÐ°Ð½ÑÐºÑÐ¸Ð¿ÑÐ¾Ð² Ð¿Ð¾Ð·Ð²Ð¾Ð»Ð¸Ñ ÑÐ°ÑÑÐ¸ÑÐ¸ÑÑ ÑÐ¿ÐµÐºÑÑ Ð¿Ð¾ÑÐµÐ½ÑÐ¸Ð°Ð»ÑÐ½ÑÑ Ð¼Ð¸ÑÐµÐ½ÐµÐ¹ Ð´Ð»Ñ ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸. ÐÐ° ÑÐµÐ³Ð¾Ð´Ð½ÑÑÐ½Ð¸Ð¹ Ð´ÐµÐ½Ñ Ðº ÑÑÐ´Ñ ÐºÐ¸Ð½Ð°Ð·, Ð·Ð°Ð´ÐµÐ¹ÑÑÐ²Ð¾Ð²Ð°Ð½Ð½ÑÑ Ð² Ð¾Ð±Ð½Ð°ÑÑÐ¶ÐµÐ½Ð½ÑÑ Ð¿ÐµÑÐµÑÑÑÐ¾Ð¹ÐºÐ°Ñ ÑÐ¶Ðµ Ð½Ð°Ð¹Ð´ÐµÐ½Ñ Ð¸Ð»Ð¸ Ð¿ÑÐ¾Ð²Ð¾Ð´ÑÑÑÑ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð¿Ð¾ Ð¿Ð¾Ð¸ÑÐºÑ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÐ¾Ð². Ð ÐµÐ·ÑÐ»ÑÑÐ°ÑÑ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ð¹ Ð¾Ð¿ÑÐ±Ð»Ð¸ÐºÐ¾Ð²Ð°Ð½Ñ Ð² Abstract Book of the ESMO Congress 2022 (9-13 September 2022, Paris, France). Annals of Oncology, 2022, Vol. 33, Suppl. 7, P. S553-S554 (25P) Ð¸ Ð² Ð¶ÑÑÐ½Ð°Ð»Ðµ Â«ÐÐ¾Ð¿ÑÐ¾ÑÑ Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸Ð¸Â», 2022, Ð¢. 68, â S3, Ð¡. 324-325. Ð ÐµÐ·ÑÐ»ÑÑÐ°ÑÑ ÑÐ°Ð±Ð¾ÑÑ Ð¿ÑÐ¸Ð½ÑÑÑ Ðº Ð¿Ð¾ÑÑÐµÑÐ½Ð¾Ð¼Ñ Ð´Ð¾ÐºÐ»Ð°Ð´Ñ Ð½Ð° Ð¼ÐµÐ¶Ð´ÑÐ½Ð°ÑÐ¾Ð´Ð½ÑÑ ÐºÐ¾Ð½ÑÐµÑÐµÐ½ÑÐ¸Ñ 35 th European congress of Patholigy. Ð¢Ð°ÐºÐ¶Ðµ Ð³Ð¾ÑÐ¾Ð²ÑÑÑÑ Ð½Ð¾Ð²ÑÐµ Ð¿ÑÐ±Ð»Ð¸ÐºÐ°ÑÐ¸Ð¸.
description: This work is devoted to the topical issue of identifying new targets for target therapy of lung cancer. The aim of this work is to find new somatic activating translocations involving genes encoding proteins with kinase activity, which can be potential targets for targeted therapy with kinase inhibitors in the treatment of lung cancer, which occupies the leading position in the structure of cancer mortality. RNA extraction from the samples was performed with commercial kits in the case of targeted sample sequencing (NGS) and with phenol-chloroform in the case of screening for translocations found by polymerase chain reaction on an expanded sample of lung cancer samples. The quality of the samples was assessed by fragment analysis and fluorometric analysis. Various Internet resources, atlases, and databases were also used for the analytical work. In the course of the work a collection of lung tumors was formed to search for new targets of targeted therapy. A sample of 101 lung tumor samples without characteristic activating events was examined by NGS. As a result, 27 chimeric transcripts without frameshift were detected, 21 of which had a partially/fully conserved kinase domain. PCR was able to verify 17 rearrangements for the presence of which 1,069 retrospective sequenced lung cancer samples were tested, where no driver mutations characteristic of this neoplasia were found. This work was able to detect 2 recurrent translocations: ADK::KAT6B and RPS6KB1::VMP1. Identification of new repetitive rearrangements and significant unique chimeric transcripts will expand the range of potential targets for targeted therapies. To date, a number of kinases involved in the discovered rearrangements have already been found or research is underway to find inhibitors. The results are published in the Abstract Book of the ESMO Congress 2022 (September 9-13, 2022, Paris, France). Annals of Oncology, 2022, Vol. 33, Suppl. 7, P. S553-S554 (25P) and in the journal Voprosy Oncologii, 2022, Vol. 68, No. S3, P. 324-325. The results of this work have been accepted for a poster presentation at the 35th European Congress of Pathology International Conference. New publications are also being prepared.